GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » ROE % Adjusted to Book Value

BCAX (Bicara Therapeutics) ROE % Adjusted to Book Value : -8.67% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Bicara Therapeutics ROE % Adjusted to Book Value?

Bicara Therapeutics's ROE % for the quarter that ended in Dec. 2024 was -16.74%. Bicara Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was 1.93. Bicara Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -8.67%.

Bicara Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for Bicara Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bicara Therapeutics ROE % Adjusted to Book Value Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
- - -20.53

Bicara Therapeutics Quarterly Data
Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial - - - -15.36 -8.67

Competitive Comparison of Bicara Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Bicara Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bicara Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bicara Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Bicara Therapeutics's ROE % Adjusted to Book Value falls into.


;
;

Bicara Therapeutics ROE % Adjusted to Book Value Calculation

Bicara Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-39.63% / 1.93
=-20.53%

Bicara Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-16.74% / 1.93
=-8.67%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Bicara Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Bicara Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bicara Therapeutics Inc (NAS:BCAX) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
FTRE COGT AVXL PRTA LENZ ABCL GHRS PRAX QURE ABUS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Website
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.